Tags : Immunotherapy Pipeline

BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline

Tuba Khan January 17, 2020

Shots: BioNtech to acquire Neon in an all-stock transaction for $67M or $2.18/ share of Neon based on the closing price of BioNTechs’ ADS of $34.55 & at a premium […]readmore

Tags : Immunotherapy Pipeline

BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Immunotherapy Pipeline

BioNTech To Acquire Neon to Bolster its Immunotherapy Pipeline

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company